8-K
filed October 15, 2024, 7:59 PM ET
CIK 0001603207
other material
confidence high
sentiment negative
materiality 1.00
Notable Labs, Ltd.: going-concern / distress — Notable Labs files Chapter 7 bankruptcy; all directors resign, officers terminated
Notable Labs, Ltd.
- Filed voluntary Chapter 7 petitions on Oct 13, 2024, in Delaware Bankruptcy Court for itself and four subsidiaries.
- A Chapter 7 trustee will be appointed to liquidate assets and pay claims under the Bankruptcy Code.
- All directors (Tuomo Pätsi, Dubin, Feinberg, Galen, Graney, Rice) resigned effective Oct 13 upon filing.
- CFO Scott A. McPherson, CSO Joseph Wagner, and interim CEO/restructuring officer Kaile A. Zagger terminated Oct 8.
- Company has no board members remaining; operations effectively cease.
Key facts
Extracted from this filing and checked against the source text.
Distress & Bankruptcy
SEC 8-K Item 1.03
confidence 0.9
Notable Labs, Ltd. entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2024-10-13).
- Proceeding
- chapter 7
- Court
- United States Bankruptcy Court for the District of Delaware
- Petition
- 2024-10-13
Exact text from the filing
After considering strategic alternatives, Notable Labs, Ltd. (the “ Company ” or “ Notable ”) and its subsidiaries filed a voluntary petition for relief (the “ Petitions ”) under the provisions of chapter 7 of title 11 of the United States Code, 11 U.S.C. §§ 101, et seq. (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on October 13, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Feinberg resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas I. H. Dubin resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tuomo Pätsi resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michele Galen resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kaile A. Zagger was terminated as Chief Restructuring Officer and Interim Chief Executive Officer at Notable Labs, Ltd..
- Action
- terminated
- Role
- Chief Restructuring Officer and Interim Chief Executive Officer
Exact text from the filing
The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott A. McPherson was terminated as Chief Financial Officer at Notable Labs, Ltd..
- Action
- terminated
- Role
- Chief Financial Officer
Exact text from the filing
The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Rice resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Graney resigned as Director at Notable Labs, Ltd..
- Action
- resigned
- Role
- Director
Exact text from the filing
Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joseph Wagner was terminated as Chief Scientific Officer at Notable Labs, Ltd..
- Action
- terminated
- Role
- Chief Scientific Officer
Exact text from the filing
The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.